Joseph S. McCracken - 27 Aug 2021 Form 4 Insider Report for Kindred Biosciences, Inc.

Role
Director
Signature
/s/ Joseph S. McCracken
Issuer symbol
N/A
Transactions as of
27 Aug 2021
Net transactions value
-$233,285
Form type
4
Filing time
30 Aug 2021, 14:55:59 UTC
Previous filing
13 Aug 2021
Next filing
14 Dec 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KIN Stock Option (right to buy) Disposed to Issuer $0 -41,890 -100% $0.000000* 0 27 Aug 2021 Common Stock 41,890 $9.65 Direct F1
transaction KIN Stock Option (right to buy) Disposed to Issuer $0 -10,000 -100% $0.000000* 0 27 Aug 2021 Common Stock 10,000 $11.00 Direct F2
transaction KIN Stock Option (right to buy) Disposed to Issuer $0 -48,500 -100% $0.000000* 0 27 Aug 2021 Common Stock 48,500 $9.91 Direct F3
transaction KIN Stock Option (right to buy) Disposed to Issuer $0 -48,500 -100% $0.000000* 0 27 Aug 2021 Common Stock 48,500 $9.84 Direct F4
transaction KIN Stock Option (right to buy) Disposed to Issuer $233,285 -48,500 -100% $4.81 0 27 Aug 2021 Common Stock 48,500 $4.44 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Joseph S. McCracken is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 This option provided for vesting in four equal quarterly installments from the option grant date. This option was cancelled pursuant to the agreement and plan of merger, dated as of June 15, 2021, by and among the Elanco Animal Health Incorporated, Knight Merger Sub, Inc., and Kindred Biosciences, Inc. (the "Merger Agreement") in exchange for no consideration.
F2 This option provided for vesting in four equal quarterly installments from the option grant date. This option was cancelled pursuant to the Merger Agreement in exchange for no consideration.
F3 This option provided for vesting in four equal quarterly installments from the option grant date. This option was cancelled pursuant to the Merger Agreement in exchange for no consideration.
F4 This option provided for vesting in four equal quarterly installments from the option grant date. This option was cancelled pursuant to the Merger Agreement in exchange for no consideration.
F5 This option provided for vesting in four equal quarterly installments from the option grant date. Pursuant to the Merger Agreement, the unvested portion of this option was subject to acceleration of vesting. This option was cancelled pursuant to the Merger Agreement in exchange for a cash payment of $233,285.00, representing the difference between the per share exercise price of the option and the merger consideration of $9.25 per share.